Eisai is a global leading research-based pharmaceutical company driven by “giving first thought to patients and their families and increasing the benefits that health care provides”. Eisai is committed to research and development and has an exciting pipeline from new discoveries, acquired molecules and further development of licensed products within Neurology, Gastroenterology, Critical Care and
Oncology. With operations in U.S., Asia, Europe and the domestic market of Japan, Eisai employs 11.000 people worldwide. The Nordic headquarter is in Sweden, Danderyd, north of Stockholm.
Further information about the company in Europe can be found on http://www.eisai.eu.


Medical Science Liaison - Neurology, Finland

Take the opportunity to become part of a highly experienced, professional and dedicated team working together to continue developing Eisai's very exciting, promising and important product portfolio in neurology for patients and their families.

Eisai has a very interesting pipeline and is fully committed to maintaining a long-term position in the area of Neurology.

Alzheimer´s disease
Eisai has a very interesting pipeline within dementia. Three compounds for Alzheimer’s disease in different stages of clinical development.
Lecanemab - an investigational anti-amyloid beta (Aβ) protofibril antibody. In the U.S, lecanemab was granted traditional approval by the U.S. Food and Drug Administration (FDA) on July 6, 2023. In Japan, Eisai received approval from the Ministry of Health, Labour and Welfare (MHLW) on September 25, 2023 to manufacture and market of lecanemab as a treatment for slowing progression of MCI and mild dementia due to AD. Eisai has also submitted applications for approval of lecanemab in EU, China, Canada, Great Britain, Australia, Switzerland, South Korea and Israel. In China and Israel, the applications have been designated for priority review, and in Great Britain, lecanemab has been designated for the Innovative Licensing and Access Pathway.

Inovelon® (rufinamide) – adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients from1 year and older.
Fycompa® (perampanel) first-in-class AMPA receptor antagonist, for adjunctive treatment of focal seizures, with or without secondary generalisation, in patients from 4 years of age and in primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy in patients from 7 years of age.

Opportunities with the role
Eisai is a growing company worldwide and in the Nordic and European region. In the expansion and development of the company, Eisai maintains full focus on the hhc philosophy (human health care), which means a full commitment to deliver health to patients and their families. This is reflected in the spirit and the positive culture that you find among Eisai employees. Eisai encourages employees to engage and spend time with patients to be able to truly understand patients’ situations and simply do good for patients. You will be part of an experienced and professional Nordic team with a great spirit.

Eisai has full commitment to further develop medicines within the Neurology area and a promising portfolio within Alzheimer’s disease. The role will be key to bring the portfolio to patients and physicians in the Nordic region.

Experience and qualifications required
• MSc in Pharmacy, Pharmacology or Bio-medical sciences. PhD or Medical degree is advantageous.
• Experience within neurodegenerative diseases is advantageous.
• Intimate knowledge of regional therapy infrastructure including key opinion leaders, major centres, market access and other related activities.
• Adequate clinical knowledge is essential.
• Industry experience from similar positions is highly advantageous.
• Launch experience is highly advantageous.

For inquires and more information about the position, please contact Jarl Molin, Recruitment Consultant at PeakSearch.

Contact details
Jarl Molin
e-mail: jarl.molin@peaksearch.se
mobile: +46 (0)70-560 20 56